‘The Market for Age-related Macular Degeneration and Diabetic Retinopathy Drugs Will Reach $5084m by 2014′ Says Latest visiongain Report
By Visiongain, PRNESunday, July 10, 2011
LONDON, July 11, 2011 -
www.visiongain.com/Report/642/Macular-Degeneration-%28AMD%29-and-Diabetic-Retinopathy-%28DR%29-World-Drug-Market-2011-2021
A new report by visiongain, a London-based business information
provider, predicts that the market for age-related macular
degeneration (AMD) and diabetic retinopathy (DR) drugs will reach
$5084m by 2014. This will make retinal diseases the most
lucrative sector of the ophthalmic drugs market, overtaking the
glaucoma sector.
The AMD and DR market generated $3173m in 2010, according to
Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World
Drug Market 2011-2021, published in July 2011.
AMD and DR are disorders of the retina which can lead to
blindness. Between them they caused over 13% of all global cases of
blindness, according to the most recent WHO assessment. Both AMD
and DR will become more widespread in the coming decades, as the
world’s population ages and the global diabetes epidemic
continues.
Genentech’s development of Lucentis (ranibizumab) made the ‘wet’
form of AMD effectively treatable for the first time. The
blockbuster success of Lucentis spurred investment in R&D for
retinal diseases. In 2011, new products for wet AMD, as well as
treatments for the ‘dry’ form of AMD, and for DR and diabetic
macular oedema, are all nearing approval.
August will see the approval of Eylea (aflibercept), Regeneron
Pharmaceuticals’ new AMD treatment. This will be the most important
new product in the AMD and DR sector since the launch of Lucentis.
Dr James Evans, healthcare industry analyst, says: “Lucentis has
shown that the industry can achieve serious clinical and commercial
success in retinal disease treatment. There were fears that
Lucentis would be derailed by the off-label use of Avastin, but the
signs now are that Lucentis will continue to grow despite the
cheaper competition. The release of Eylea is the next major stage
in the development of this market, and it will encourage further
investment in an already exciting pipeline.”
Visiongain’s research suggests that scientific study of retinal
diseases will yield more important insights in the next ten years.
While Lucentis and Eylea target vascular endothelial growth factor
(VEGF), products with new targets will gain importance as
monotherapies and in combination with VEGF inhibitors.
Visiongain predicts that the AMD and DR market will grow
steadily to 2021, with treatments for dry AMD and DR answering the
serious unmet needs in the sector. This new report complements
visiongain’s wide range of analytical reports in healthcare and
other industries.
For more information about this critical report please click on:
www.visiongain.com/Report/642/Macular-Degeneration-%28AMD%29-and-Diabetic-Retinopathy-%28DR%29-World-Drug-Market-2011-2021
To request an executive summary of this report please speak to
Sara Peerun:
Email:
Tel: +44(0)20-7336-6100
Web:
Table of Contents
1. Executive Summary
1.1 Macular Degeneration (AMD) and Diabetic Retinopathy (DR):
Market Overview
1.2 Contents of this Report
1.3 Research and Analysis Methods
2. AMD and DR: An Introduction
2.1 The Biology of Vision
2.1.1 The Human Eye
2.1.2 The Retina and the Vision Process
2.2 Age-Related Macular Degeneration (AMD)
2.2.1 Early Stages of AMD
2.2.2 Advanced Dry AMD (Geographic Atrophy)
2.2.3 Wet AMD
2.2.4 Causes and Risk Factors for AMD
2.3 Diabetic Retinopathy (DR)
2.3.1 Causes and Types of Diabetic Retinopathy
2.3.2 Non-Proliferative Diabetic Retinopathy
2.3.3 Diabetic Macular Oedema
2.3.4 Proliferative Diabetic Retinopathy
2.3.5 Risk Factors for Diabetic Retinopathy
2.4 Diagnosis
2.5 Epidemiology
3. The Global AMD and DR Market 2011-2021
3.1 Global AMD and DR Market, 2011-2021
3.2 Market Breakdown, 2011-2021
3.3 The Ophthalmic Market, 2011-2021
3.3.1 Other Retinal Disorders
4. Regional AMD and DR Markets 2011-2021
4.1 The US Dominated the AMD and DR Drug Market in 2010
4.2 The US: Leading the AMD and DR Market, 2011-2021
4.2.1 Forecast for the US Market, 2011-2021
4.3 Japan: Second-Largest Market, 2011-2021
4.3.1 Forecast for the Japanese Market, 2011-2021
4.4 The EU Top Five: Rising Healthcare Costs, 2011-2021
4.4.1 Forecast for the French Market, 2011-2021
4.4.2 Forecast for the German Market, 2011-2021
4.4.3 Forecast for the UK Market, 2011-2021
4.4.4 Forecast for the Spanish Market, 2011-2021
4.4.5 Forecast for the Italian Market, 2011-2021
4.5 India: Diabetes Epidemic Drives the Market, 2011-2021
4.5.1 Forecast for the Indian Market, 2011-2021
4.6 China: The Fastest-Growing Market, 2011-2021
4.6.1 Forecast for the Chinese Market, 2011-2021
5. Leading Products in the AMD and DR Market 2011-2021
5.1 Lucentis Dominates the Market in 2011
5.2 Lucentis (Roche/Novartis): Most Successful Ophthalmic
Drug
5.2.1 Forecast for Lucentis, 2011-2021
5.3 Visudyne (QLT / Novartis): Treatment for Classic AMD
5.3.1 Forecast for Visudyne, 2011-2021
5.4 Avastin (Roche): Off-Label Competitor to Lucentis
5.4.1 The CATT Study: The Verdict on Avastin versus Lucentis
5.4.2 Forecast for Avastin, 2011-2021
5.5 Macugen (Pfizer): Alternative VEGF Antagonist
5.5.1 Forecast for Macugen, 2011-2021
5.6 Eylea (Regeneron/Bayer): The Next Blockbuster
5.6.1 Forecast for Eylea, 2011-2021
5.7 Other Products in the Market
5.7.1 Treatments for Dry AMD
5.7.2 Treatments for DR
5.7.2.1 Triamcinolone Acetonide (Various Companies)
5.7.2.2 Lisinopril (Various Companies)
5.7.2.3 Avastin (Roche)
5.7.2.4 Dobesilate (Various Companies)
5.7.3 Forecast for Other Products in the Market, 2011-2021
6. The AMD and DR Product Pipeline, 2011
6.1 AMD Products
6.1.1 Eylea (Regeneron/Bayer)
6.1.2 Posurdex/SK-503 (Allergan)
6.1.3 Bevasiranib/Cand5 (OPKO)
6.1.4 Pazopanib (GlaxoSmithKline)
6.1.5 NT501 (Neurotech)
6.1.6 Zybrestat (Oxigene/Symphony ViDA)
6.1.7 Brimonidine (Allergan)
6.1.8 Sirolimus (MacuSight/Santen)
6.1.9 Iluvien (Alimera/pSivida)
6.1.10 RTP801i-14/PF-4523655/PF-655 (Quark/Silence/Pfizer)
6.1.11 AGN-745/SIRNA-027 (Merck & Co./Allergan)
6.1.12 ATG-3 (CoMentis)
6.1.13 OT-551 (Othera)
6.1.14 Fenretinide (Sirion Therapeutics)
6.1.15 Early-Stage Products
6.2 DR Products
6.2.1 Arxxant (Eli Lilly/Alcon/Takeda)
6.2.2 Vitreosolve (Vitreoretinal Technologies)
6.2.3 Atacand/TCV-116 (AstraZeneca/Takeda)
6.2.4 Microplasmin (Thrombogenics)
6.2.5 Products Also Indicated for AMD
6.2.6 Early-Stage DR Products
7. Leading Companies in the AMD and DR Market, 2011
7.1 Pharmaceutical Industry Leaders
7.1.1 Novartis
7.1.2 Roche
7.1.3 Pfizer
7.1.4 Sanofi
7.1.5 Other Big Pharma Players
7.2 Smaller Companies
7.2.1 Allergan
7.2.2 BioDiem
7.2.3 CoMentis
7.2.4 Alimera Sciences
7.2.5 Gene Signal
7.2.6 GenVec
7.2.7 ISTA Pharmaceuticals
7.2.8 Shire
7.2.9 KAI Pharmaceuticals
7.2.10 Lpath
7.2.11 Santen
7.2.12 Neurotech
7.2.13 Ophthotech Corporation
7.2.14 OPKO Health
7.2.15 Othera Pharmaceuticals
7.2.16 Oxford BioMedica
7.2.17 Oxigene
7.2.18 Potentia
7.2.19 Regeneron
7.2.20 Sirion Therapeutics
7.2.21 Sirnaomics
7.2.22 AmpliPhi Biosciences Corporation
7.2.23 ThromboGenics
8. The AMD and DR Market: Qualitative Analysis
8.1 The AMD and DR Market is Well Established and Growing
8.2 Products are Few, Inconvenient and Expensive, Some People
Believe
8.3 Global Demography and the Diabetes Epidemic Mean Governments
Will Keep Paying
8.4 Is Pharmaceutical Treatment the Future for Ophthalmics
Disorders?
9. Research Interviews
9.1 Interview with Professor David T. Shima, University College
London
9.1.1 On the Role of VEGF in Retinal Disorders
9.1.2 On Candidate Molecule E10030
9.1.3 On Candidate Molecule JSM 6427
9.1.4 On New Sustained Release Formulations
9.1.5 On Delta-Notch Signalling
9.1.6 On Potential Clinical Crossovers Between Ophthalmology and
Oncology
9.1.7 On the Commercial and Clinical Possibilities in the
Ophthalmology Market
9.1.8 On the Possibilities of Research into the Endothelial
Fenestra
9.2 Interview with Dr Edward Feener, Joslin Diabetes Center
9.2.1 On the Kallikrein Pathway in Disease Etiology
9.2.2 On the Use of Proteomics in Research
9.2.3 On Challenges in Diabetic Retinopathy
9.2.4 On Plasma Kallikrein Inhibitors, Prevention, and Other Future
Prospects in the Sector
9.3 Interview with Dr Paul Ashton, pSivida
9.3.1 On the Challenge of Getting Drugs to the Retina
9.3.2 On pSivida’s Drug Delivery Platforms
9.3.3 On Lucentis, Avastin and VEGF-Trap
10. Conclusions
10.1 The AMD and DR Market is Likely to Expand
10.2 The Issue of Avastin versus Lucentis Has Dominated the
Sector
10.3 Regeneron’s Eylea as the Next New Product on the Market
10.4 The Pipeline for AMD and DR is Rich and Diverse
10.5 Concluding Remarks
About visiongain
Visiongain is one of the fastest growing and most innovative
independent media companies in Europe. Based in London, UK,
visiongain produces a host of business-2-business conferences,
newsletters, management reports and e-zines focusing on the
Pharmaceutical, Telecoms, Energy, Defence and Materials
sectors.
Visiongain publishes reports produced by its in-house analysts,
who are qualified experts in their field. Visiongain has firmly
established itself as the first port-of-call for the business
professional, who needs independent, high quality, original
material to rely and depend on.
Notes for Editors
If you are interested in a more detailed overview of this report,
please send an e-mail to sara.peerun@visiongainglobal.com or call
her on +44(0)207-336-6100
.
Tags: July 11, London, United Kingdom, Visiongain
